Article

PDF
Access to the PDF text
Advertising



Archives of cardiovascular diseases
Volume 106, n° 3
pages 135-145 (mars 2013)
Doi : 10.1016/j.acvd.2012.12.001
Received : 22 October 2012 ;  accepted : 4 December 2012
Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: Results of the randomized Intra-Co-EpoMI trial
Administration intracoronaire de darbépoétine-alpha au moment de la reperfusion au cours de l’infarctus aigu du myocarde : résultats de l’essai Intra-Co-EpoMI
 

Figure 1




Figure 1 : 

Flowchart representing number of patients randomized to darbepoetin-alpha (DA) or control and patients who dropped out for provided reasons. TIMI: thrombolysis in myocardial infarction.


Figure 2




Figure 2 : 

Primary endpoint: level of serum creatine kinase (CPK) in patients treated with darbepoetin-alpha (DA) and in patients in the control group after successful reperfusion: (A) peak and (B) area under the curve (AUC). NS: not significant.


Figure 3




Figure 3 : 

Level of serum creatine kinase (CPK) in patients treated with darbepoetin-alpha (DA) and in patients in the control group after successful reperfusion adjusted to the size of the area at risk with three different scores (cardiac magnetic resonance [CMR] score, BARI score and modified APPROACH score): (A) peak and; (B) area under the curve (AUC). NS: not significant.


Figure 4




Figure 4 : 

a: area of hyperenhancement on cardiac magnetic resonance (CMR) measured between 3 and 7days after myocardial infarction and expressed as a percentage of the left ventricular myocardium in patients treated with darbepoetin-alpha (DA) and in patients in the control group after successful reperfusion; b: area of hyperenhancement on CMR adjusted to the size of the area at risk with three different scores (CMR score, BARI score and modified APPROACH score). NS: not significant.


Figure 5




Figure 5 : 

A. Area of hyperenhancement on cardiac magnetic resonance (CMR) measured 3months after infarction and expressed as a percentage of the left ventricular myocardium in patients treated with darbepoetin-alpha (DA) and in patients in the control group after successful reperfusion. B. Area of hyperenhancement on CMR adjusted to the size of the area at risk with three different scores (CMR score, BARI score and modified APPROACH score). NS: not significant.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline